London Daily

Focus on the big picture.
Monday, Jun 23, 2025

‘Paradigm shift’ in cancer treatment as Moderna’s vaccine shows promise

‘Paradigm shift’ in cancer treatment as Moderna’s vaccine shows promise

Preliminary results raise hope of fundamental change in cancer treatment.

The technology that saved the day during the COVID-19 pandemic is on the cusp of doing the same for cancer.

Preliminary results from Moderna's ongoing trial of a personalized mRNA cancer vaccine given alongside an immunotherapy from MSD showed a “statistically significant and clinically meaningful reduction in the risk of disease recurrence or death,” the company said Tuesday.

The positive results from the phase 2b trial that tested the vaccine's efficacy and safety paves the way for the final stage of research and then potentially a future approval for the first mRNA cancer vaccine.

Moderna became a household name during the pandemic when its mRNA vaccine became one of two vaccines of choice for many countries. But while the company was delivering hundreds of millions of COVID-19 vaccines around the world, it was also working on trials of its pipeline of different types of cancer vaccines, including one that targets specific gene mutations.

Leading the pack is the company's personalized cancer vaccine. The vaccine, which is being delivered alongside MSD’s immunotherapy Keytruda, is meant to stimulate an immune response based on a patient’s specific tumor. Keytruda then helps the patient’s immune cells to more effectively fight the cancer. The hope was that by working together, the vaccine and the immunotherapy would be able to “bring the power of the immune system to bear on the cancer and to kill it,” said Moderna’s Chief Medical Officer Paul Burton in an interview with POLITICO.

While the current trial is testing the vaccine for melanoma, Moderna is planning additional studies to test it on other cancers. Speaking before the results were released, Burton said that if the trial succeeded it would “be a new paradigm shift, [a] foundational shift that we haven't seen for at least a decade, in a new therapeutic approach for cancer.”

Those hopes appear to have been realized. Preliminary results released today of the trial of 157 melanoma patients indicate that the risk of recurrence of cancer or death was 44 percent lower in those receiving both the vaccine and Keytruda compared to those receiving the immunotherapy alone. The next step is to publish the full data set and start discussions with regulators. Moderna and MSD plan to begin the larger phase 3 trial, which will test effectiveness in more people, in 2023 and “rapidly expand to additional tumor types.”

Cancer is the next major target for mRNA jabs, with companies like Moderna and BioNTech working to prove that their jabs can both outperform existing immunotherapies delivered on their own and provide value to cash-strapped health systems.


Cancer as a chronic disease


What makes the mRNA technology unique is that it can bring together 20 to 30 antigens — substances that trigger an immune response in the body. That's something that's fundamental to the potential success of the vaccine, as it means the immune system is shown a whole range of antigens that the tumor is expressing. “I can’t imagine how you can do that with any other technology,” said Burton.

Unlike Moderna’s COVID-19 vaccine which is “off the shelf” and not tailored to each individual patient, Moderna's personalized cancer vaccine is “supremely complex,” said Burton as “it’s really making a medicine for each individual person.”

The aim? For certain patients in the earlier stage of their disease, the hope is the treatment could potentially prevent the disease from progressing. In patients with more advanced disease, the desire is to extend their life, with their cancer becoming something of a chronic disease.

“We would hope that if we can really prove this, that it will be a fundamental shift in the way that — at least for certain kinds of cancer — we treat them and the clinical benefit could really be profound,” said Burton.

The other factor is side effects. Or rather, the relative lack of them compared to, say, chemotherapy drugs. “If you can get real clinical benefit with a really manageable safety profile, I really think could be transformational," said the chief medical officer. The topline results on Tuesday indicate that the adverse events were consistent with those reported in the phase 1 trial, which found the vaccine had an acceptable safety profile.

One of the major obstacles with immunotherapies is the price. There’s concern that the same will happen with mRNA cancer vaccines. While these kinds of decisions are some way off, it’s a concern that Sam Godfrey, senior research information manager at Cancer Research U.K. (CRUK), previously expressed concern about.

“If something's costing a million pounds per treatment for a personalized vaccine, and its effectiveness isn't much better than standard chemotherapy, which doesn't cost very much, you've got that decision about, actually, is this worth investing in?” said Godfrey earlier this year.

Moderna’s Burton said he had not yet been in discussions around price. But he argued that mRNA has “huge potential” to bring value to many people around the world. “We want to bring equitable health care to people all around the world,” he said. “So we want to work with governments and with payers to do that, but I think it's premature yet to really think about price.”

Comments

Oh ya 3 year ago
If anyone takes a shot for anything after what has come out about the covid19 shot you deserve the blood clots and sudden death syndrome. You failed one world IQ test don't fail another

Newsletter

Related Articles

0:00
0:00
Close
Starmer Invites Innovators to Join Government Talent Scheme
UK Economy’s Strong Opening Quarter Shows Signs of Cooling
Harrods Seeks Court Order to Secure Al Fayed Estate for Victims
BA and Singapore Airlines Cancel Dubai Flights Amid Middle East Tensions
Trump Faces Backlash from MAGA Base Over Iran Strikes
Meta Bets $14 B on Alexandr Wang to Drive AI Ambitions
WATCH: Israeli forces show the aftermath of a massive airstrike at Iran's Isfahan nuclear site
FedEx Founder Fred Smith, ‘Heart and Soul’ of the Company, Dies at 80
Chinese Factories Shift Away from U.S. Amid Trump‑Era Tariffs
Pimco Seizes Opportunity in Japan’s Dislocated Bond Market
Labubu Doll Drives Pop Mart to Status as China’s Most Valuable Toy Maker
Global Coal Demand Defies Paris Accord Goals
We have new information and breaking details to share about what is shaping up to be a historic air campaign tonight
Six Massive Bombs Dropped on Fordow; Trump: 'A Historic Moment for the U.S., Israel, and the World'
Fordow: Deeply Buried Iranian Enrichment Site in U.S.–Israel Crosshairs
United States Conducts Precision Strikes on Iran’s Nuclear Sites
US strikes Iran nuclear sites, Trump says
Pakistan to nominate Trump for Nobel Peace Prize.
BBC Demands Perplexity AI Immediately Stop Using Its Content
Telegram Founder: I Will Leave My Fortune to Over 100 of My Children
Political Turmoil Resurfaces in Belgium Amid Economic Concerns
Fed policymakers divided on timing of interest rate cuts
Trump signals imminent agreement with Harvard University
Inheritance tax referendum alarms Swiss billionaire community
Japan cancels bilateral security meeting amid US defence demands
AI skeptic Emily Bender warns that ‘the emperor has no clothes’
Israel Confirms Assassination of Quds Force Commander in Tehran
16 Billion Login Credentials Leaked in Unprecedented Cybersecurity Breach
Senate hearing on who was 'really running' Biden White House kicks off
Iranian Military Officers Reportedly Seek Contact with Reza Pahlavi, Signal Intent to Defect
FBI and Senate Investigate Allegations of Chinese Plot to Influence the 2020 Election in Biden’s Favor Using Fake U.S. Driver’s Licenses
Vietnam Emerges as Luxury Yacht Destination for Ultra‑Rich
Plans to Sell Dutch Embassy in Bangkok Face Local Opposition
China's Iranian Oil Imports Face Disruption Amid Escalating Middle East Tensions
Trump's $5 Million 'Trump Card' Visa Program Draws Nearly 70,000 Applicants
DGCA Finds No Major Safety Concerns in Air India's Boeing 787 Fleet
Airlines Reroute Flights Amid Expanding Middle East Conflict Zones
Elon Musk's xAI Seeks $9.3 Billion in Funding Amid AI Expansion
Trump Demands Iran's Unconditional Surrender Amid Escalating Conflict
Israeli Airstrike Targets Iranian State TV in Central Tehran
President Trump is leaving the G7 summit early and has ordered the National Security Council to the Situation Room
Taiwan Imposes Export Ban on Chips to Huawei and SMIC
Israel has just announced plans to strike Tehran again, and in response, Trump has urged people to evacuate
Netanyahu Signals Potential Regime Change in Iran
Juncker Criticizes EU Inaction on Trump Tariffs
EU Proposes Ban on New Russian Gas Contracts
Analysts Warn Iran May Resort to Unconventional Warfare
Iranian Regime Faces Existential Threat Amid Conflict
Energy Infrastructure Becomes War Zone in Middle East
UK Home Secretary Apologizes Over Child Grooming Failures
×